Low-dose brain radiation improves behavior, cognition in Alzheimer’s pilot study
By
Alicia Lasek
May 04, 2021
Low-dose ionizing radiation may be a promising, although possibly controversial, therapy for Alzheimer’s disease, according to the researchers behind a small new pilot study.
Survey: U.S. neurologists would prescribe Leqembi if fully approved
By
Alicia Lasek
Apr 12, 2023
A “healthy proportion” of surveyed neurologists have already begun prescribing the treatment, and nearly all said they planned to do so if traditional FDA approval is granted.
Becerra orders CMS to rethink $22 Medicare Part B premium price hike tied to Aduhelm
By
Alicia Lasek
Jan 11, 2022
With the 50% price drop of Aduhelm on January 1, there is good reason for CMS to reassess a hefty proposed premium hike for 2022, the U.S. health secretary said. On Wednesday, CMS is expected to announce...
Benefits of Alzheimer’s drug Leqembi persist when treatment is halted, trial shows
By
Alicia Lasek
Apr 09, 2023
A relative slowing of cognitive decline continues for up to two years in patients who stop taking the recently authorized drug, clinical trial data reveal.
Program that diagnosed fractures virtually led to fewer ER visits for LTC residents: study
By
Alicia Lasek
May 14, 2023
A program that enabled virtual diagnosis and on-site fracture care kept 100% of participating LTC residents out of the emergency department and cut the need for clinic visits, a new study reveals.
Pfizer, BioNTech to pursue 2nd booster shot authorization for older adults
By
Alicia Lasek
Mar 16, 2022
A second booster — or fourth dose — will be necessary to improve the vaccine’s waning protection in the face of omicron, Pfizer’s CEO has stated. Whether the FDA will find the evidence compelling...
Omicron sub-variants cut potency of monoclonal antibodies, mRNA vaccines: study
Mar 04, 2022
Eli Lilly’s bebtelovimab is the only authorized monoclonal antibody that can neutralize all three dominant sub-variants, investigators say.
FDA advisers support full approval of Paxlovid for at-risk older adults
By
Alicia Lasek
Mar 16, 2023
The antiviral drug Paxlovid should receive full FDA approval to treat COVID-19 in older adults at risk of severe outcomes, the advisers decided in a Thursday vote.
Alzheimer’s blood biomarkers not ready for primary care use, expert panel decides
By
Alicia Lasek
Aug 18, 2022
An international group of clinicians and researchers have agreed that Alzheimer’s disease blood biomarkers are a significant breakthrough, but are not yet ready for general clinical and primary care...
Staff buy-in key to reducing ED visits with telemedicine, senior living study finds
By
Alicia Lasek
Feb 23, 2021
An attempt to reduce unnecessary emergency department visits with telemedicine triage failed when senior living healthcare providers were not on board. The findings contain lessons for for clinicians and...